pubmed-article:2956199 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:2956199 | lifeskim:mentions | umls-concept:C0682523 | lld:lifeskim |
pubmed-article:2956199 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
pubmed-article:2956199 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
pubmed-article:2956199 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
pubmed-article:2956199 | lifeskim:mentions | umls-concept:C0599796 | lld:lifeskim |
pubmed-article:2956199 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
pubmed-article:2956199 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:2956199 | pubmed:dateCreated | 1987-9-14 | lld:pubmed |
pubmed-article:2956199 | pubmed:abstractText | The level of expression of the class-I major histocompatibility (MHC) antigen was determined in a series of human embryo cell lines transformed with either adenovirus 12 (Ad 12) early region I (EI) or adenovirus 5 (Ad 5) EI DNA or with combinations of Ad 12 early region IA (EIA) or Ad 2 EIA with activated N-ras DNA. MHC class-I antigen expression was greatly reduced in all Ad 12 transformants, compared to primary cells. Expression was also reduced in the Ad 5 cell lines transformed with EIA and EIB DNA, but levels were near normal in those lines with only EIA DNA present. Amounts of MHC class-I antigen on the cell surface, as determined by RIA and FACS analysis, generally reflected total cellular levels as determined by Western blotting. Expression of beta 2 microglobulin was also much reduced in those cell lines with low levels of MHC class-I antigen. The treatment of primary cells and all the transformants with human gamma-interferon resulted in increased expression of HLA on the cell surface. Infection of primary human cells with Ad 12 or with a series of Ad 12 mutants did not have any effect on the MHC class-I antigens present. | lld:pubmed |
pubmed-article:2956199 | pubmed:language | eng | lld:pubmed |
pubmed-article:2956199 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2956199 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:2956199 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2956199 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2956199 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2956199 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2956199 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2956199 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2956199 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:2956199 | pubmed:month | Aug | lld:pubmed |
pubmed-article:2956199 | pubmed:issn | 0020-7136 | lld:pubmed |
pubmed-article:2956199 | pubmed:author | pubmed-author:GrandR JRJ | lld:pubmed |
pubmed-article:2956199 | pubmed:author | pubmed-author:GallimoreP... | lld:pubmed |
pubmed-article:2956199 | pubmed:author | pubmed-author:RoweMM | lld:pubmed |
pubmed-article:2956199 | pubmed:author | pubmed-author:ByrdP JPJ | lld:pubmed |
pubmed-article:2956199 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:2956199 | pubmed:day | 15 | lld:pubmed |
pubmed-article:2956199 | pubmed:volume | 40 | lld:pubmed |
pubmed-article:2956199 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:2956199 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:2956199 | pubmed:pagination | 213-9 | lld:pubmed |
pubmed-article:2956199 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
pubmed-article:2956199 | pubmed:meshHeading | pubmed-meshheading:2956199-... | lld:pubmed |
pubmed-article:2956199 | pubmed:meshHeading | pubmed-meshheading:2956199-... | lld:pubmed |
pubmed-article:2956199 | pubmed:meshHeading | pubmed-meshheading:2956199-... | lld:pubmed |
pubmed-article:2956199 | pubmed:meshHeading | pubmed-meshheading:2956199-... | lld:pubmed |
pubmed-article:2956199 | pubmed:meshHeading | pubmed-meshheading:2956199-... | lld:pubmed |
pubmed-article:2956199 | pubmed:meshHeading | pubmed-meshheading:2956199-... | lld:pubmed |
pubmed-article:2956199 | pubmed:meshHeading | pubmed-meshheading:2956199-... | lld:pubmed |
pubmed-article:2956199 | pubmed:meshHeading | pubmed-meshheading:2956199-... | lld:pubmed |
pubmed-article:2956199 | pubmed:meshHeading | pubmed-meshheading:2956199-... | lld:pubmed |
pubmed-article:2956199 | pubmed:meshHeading | pubmed-meshheading:2956199-... | lld:pubmed |
pubmed-article:2956199 | pubmed:meshHeading | pubmed-meshheading:2956199-... | lld:pubmed |
pubmed-article:2956199 | pubmed:meshHeading | pubmed-meshheading:2956199-... | lld:pubmed |
pubmed-article:2956199 | pubmed:year | 1987 | lld:pubmed |
pubmed-article:2956199 | pubmed:articleTitle | The level of expression of class-I MHC antigens in adenovirus-transformed human cell lines. | lld:pubmed |
pubmed-article:2956199 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:2956199 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2956199 | lld:pubmed |